Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
BioAdaptives (OTC: BDPT) announces strategic shift with five new nutritional products planned for phased market entry over 6-9 months, following James Keener’s appointment as CEO in May 2024. The first product, Zeranovia, targets weight management. The company claims preliminary test results show effectiveness comparable to prescription medications with fewer side effects. BioAdaptives has applied for Institutional Review Board (IRB) approval to conduct human clinical trials, an uncommon step for nutraceutical companies, aiming to validate their product’s effectiveness through medically supervised proof.
BioAdaptives (OTC: BDPT) annuncia un cambiamento strategico con cinque nuovi prodotti nutrizionali previsti per un ingresso graduale nel mercato nei prossimi 6-9 mesi, dopo la nomina di James Keener come CEO nel maggio 2024. Il primo prodotto, Zeranovia, si concentra sulla gestione del peso. L’azienda afferma che i risultati preliminari dei test mostrano un’efficacia comparabile a quella dei farmaci da prescrizione con meno effetti collaterali. BioAdaptives ha richiesto l’approvazione del Comitato Etico (IRB) per condurre prove cliniche su esseri umani, un passo insolito per le aziende nutraceutiche, con l’obiettivo di convalidare l’efficacia del loro prodotto attraverso prove mediche supervisionate.
BioAdaptives (OTC: BDPT) anuncia un cambio estratégico con cinco nuevos productos nutricionales planeados para una entrada gradual al mercado en un plazo de 6-9 meses, tras el nombramiento de James Keener como CEO en mayo de 2024. El primer producto, Zeranovia, se enfoca en el manejo del peso. La compañía afirma que los resultados de pruebas preliminares muestran una efectividad comparable a la de los medicamentos recetados con menos efectos secundarios. BioAdaptives ha solicitado la aprobación de la Junta de Revisión Institucional (IRB) para llevar a cabo ensayos clínicos en humanos, un paso inusual para las empresas nutracéuticas, con el objetivo de validar la efectividad de su producto a través de pruebas médicas supervisadas.
BioAdaptives (OTC: BDPT)는 2024년 5월 James Keener가 CEO로 임명된 후 6-9개월 동안 단계적으로 시장에 진입할 예정인 5개의 새로운 영양 제품에 대한 전략적 전환을 발표했습니다. 첫 번째 제품인 Zeranovia는 체중 관리에 초점을 맞추고 있습니다. 회사는 초기 테스트 결과가 부작용이 적은 처방 약물에 필적하는 효능을 보여준다고 주장합니다. BioAdaptives는 영장 보호위원회(IRB)의 승인을 신청하여 인간 임상 시험을 수행하려고 합니다. 이는 건강기능식품 회사로서는 이례적인 조치로, 의학적으로 감독된 증명을 통해 제품의 효과를 검증하는 것을 목표로 하고 있습니다.
BioAdaptives (OTC: BDPT) annonce un changement stratégique avec cinq nouveaux produits nutritionnels prévus pour une entrée progressive sur le marché dans les 6 à 9 mois, suite à la nomination de James Keener au poste de PDG en mai 2024. Le premier produit, Zeranovia, vise à gérer le poids. L’entreprise affirme que les résultats préliminaires des tests montrent une efficacité comparable à celle des médicaments sur ordonnance, avec moins d’effets secondaires. BioAdaptives a demandé l’approbation du Comité d’éthique institutionnel (IRB) pour mener des essais cliniques sur l’homme, une étape peu courante pour les entreprises nutraceutiques, visant à valider l’efficacité de leur produit par des preuves médicalement supervisées.
BioAdaptives (OTC: BDPT) kündigt einen strategischen Wandel an, mit fünf neuen Nahrungsergänzungsprodukten, die über einen Zeitraum von 6-9 Monaten schrittweise auf den Markt kommen sollen, nachdem James Keener im Mai 2024 als CEO ernannt wurde. Das erste Produkt, Zeranovia, zielt auf das Gewichtsmanagement ab. Das Unternehmen behauptet, dass die vorläufigen Testergebnisse eine Wirksamkeit zeigen, die mit verschreibungspflichtigen Medikamenten vergleichbar ist, jedoch mit weniger Nebenwirkungen. BioAdaptives hat die Genehmigung der Institutional Review Board (IRB) beantragt, um klinische Studien am Menschen durchzuführen, was für nutraceutical Unternehmen einen ungewöhnlichen Schritt darstellt, um die Wirksamkeit ihres Produkts durch medizinisch überwachte Nachweise zu validieren.
Positive
- Company ready to launch 5 new products in nutritional market
- Initial test results indicate product effectiveness comparable to prescription medications
- Pursuing IRB approval for human clinical trials, potentially differentiating from competitors
Negative
- Clinical trial results pending and not guaranteed
- Product claims not yet validated by regulatory authorities
LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) — BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James Keener as CEO on May 21, 2024. Previous management retired, and Keener began focusing on products that are in demand and can change people’s lives.
Six months after Keener took over, the Company is ready for the staged rollouts of five products over the next six to nine months. This is only possible because of the work and funding invested into development over a year earlier outside of BioAdaptives®. Now, BioAdaptives® has become the vehicle for bringing these high-demand products to market.
The first is a weight management product called Zeranovia. To learn more, please visit: Zeranovia.com
“No product is in more demand today than an effective weight management product,” said Keener, adding the Company’s mission is to stay at the forefront of innovation.
Every day, commercials claim a specific supplement or food can work just as well as Ozempic®, Mounjaro®, or the generic GLP-1 and GIP. If this were true, pharmaceutical drug companies would go broke. A supplement can rarely work as well as a prescription medicine. However, BioAdaptives’ test results so far show that its product does work as well as prescription medication, with fewer side effects.
The Company has applied to an Institutional Review Board (IRB) for approval for a human clinical trial to prove what its earlier results have shown. It is rare for a nutraceutical company to undergo IRB approval and perform a human clinical trial. BioAdaptives believes IRB approval would provide the credibility to compete with the major players moving forward. The Company is cautiously optimistic that this will result in medically supervised proof.
To sign up for the trial, visit: Zeranovia.com.
Ozempic® is a trademark of Novo Nordisk, and Mounjaro® is a trademark of Eli Lilly.
About BioAdaptives, Inc.
BioAdaptives, Inc. (OTC: BDPT) is a leader in the nutritional products industry, committed to delivering innovative solutions that enhance quality of life, anti-aging, cell repair, and well-being. With a deep focus on research, customer insights, and sustainable practices, BioAdaptives, Inc. is redefining what customers can expect from nutritional products. For more information, visit www.bioadaptives.com.
Forward-Looking Statements:
This press release contains forward-looking statements, including those related to the anticipated performance and success of the new product line. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our filings with the Securities and Exchange Commission for more information on potential risks.
This launch is expected to establish BioAdaptives, Inc. as an industry innovator dedicated to bringing scientifically advanced, market-aligned solutions to customers worldwide.
Contact:
Emily Harrison
Investor Relations
BioAdaptives, Inc.
(702) 659-8829
Info@bioadaptives.com
Wire Service Contact:
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
FAQ
What new products is BioAdaptives (BDPT) launching in 2024?
BioAdaptives (BDPT) is launching five nutritional products over 6-9 months, starting with Zeranovia, a weight management product.
When did James Keener become CEO of BioAdaptives (BDPT)?
James Keener was appointed CEO of BioAdaptives (BDPT) on May 21, 2024.
What is Zeranovia by BioAdaptives (BDPT)?
Zeranovia is BioAdaptives’ weight management product that claims effectiveness comparable to prescription medications with fewer side effects, pending clinical trials.
Is BioAdaptives (BDPT) conducting clinical trials for Zeranovia?
BioAdaptives has applied for IRB approval to conduct human clinical trials for Zeranovia to validate its effectiveness.
